Home  /  Resource Library  /  Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single arm, open-label, phase 2 study

Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single arm, open-label, phase 2 study

Results of a phase II study investigating acalabrutinib combined with venetoclax and obinutuzimab for first line treatment of CLL.